MA32898B1 - Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone - Google Patents

Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone

Info

Publication number
MA32898B1
MA32898B1 MA33939A MA33939A MA32898B1 MA 32898 B1 MA32898 B1 MA 32898B1 MA 33939 A MA33939 A MA 33939A MA 33939 A MA33939 A MA 33939A MA 32898 B1 MA32898 B1 MA 32898B1
Authority
MA
Morocco
Prior art keywords
receptor
arylmethylbenzoquinazolinone
positive allosteric
allosteric modulators
compounds
Prior art date
Application number
MA33939A
Other languages
Arabic (ar)
English (en)
Inventor
Scott D Kuduk
Douglas C Beshore
Marco Christina Ng Di
Thomas J Greshock
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32898B1 publication Critical patent/MA32898B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/19—Acids containing three or more carbon atoms
    • C07C53/21—Acids containing three or more carbon atoms containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention se rapporte à des composés de type benzoquinazolinone de formule (I) qui sont des modulateurs allostériques positifs du récepteur M1 et qui sont utiles pour le traitement de maladies dans lequel le récepteur M1 est mis en jeu, tel que la maladie d'Alzheimer, la schizophrénie, la douleur ou les troubles du sommeil. L'invention porte également sur des compositions pharmaceutiques comprenant les composés et sur l'utilisation des composés et des compositions pour le traitement de maladies médiées par le récepteur M1.
MA33939A 2008-11-20 2011-06-13 Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone MA32898B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19974008P 2008-11-20 2008-11-20
PCT/US2009/065060 WO2010059773A1 (fr) 2008-11-20 2009-11-19 Modulateurs allostériques positifs du récepteur m1 d’arylméthylbenzoquinazolinone

Publications (1)

Publication Number Publication Date
MA32898B1 true MA32898B1 (fr) 2011-12-01

Family

ID=41565956

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33939A MA32898B1 (fr) 2008-11-20 2011-06-13 Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone

Country Status (36)

Country Link
US (4) US8557832B2 (fr)
EP (1) EP2358686B1 (fr)
JP (1) JP5102397B2 (fr)
KR (1) KR101305590B1 (fr)
CN (1) CN102292323B (fr)
BR (1) BRPI0921924A2 (fr)
CA (1) CA2743562C (fr)
CO (1) CO6361928A2 (fr)
CR (1) CR20110268A (fr)
CY (1) CY1113665T1 (fr)
DK (1) DK2358686T3 (fr)
DO (1) DOP2011000135A (fr)
EA (1) EA019098B1 (fr)
EC (1) ECSP11011066A (fr)
ES (1) ES2393694T3 (fr)
GE (1) GEP20156348B (fr)
GT (1) GT201100127A (fr)
HN (1) HN2011001358A (fr)
HR (1) HRP20120992T1 (fr)
IL (1) IL212573A (fr)
MA (1) MA32898B1 (fr)
MX (1) MX2011005284A (fr)
MY (1) MY162502A (fr)
NI (1) NI201100100A (fr)
NZ (1) NZ592961A (fr)
PE (1) PE20120031A1 (fr)
PL (1) PL2358686T3 (fr)
PT (1) PT2358686E (fr)
RS (1) RS52528B (fr)
SG (1) SG171769A1 (fr)
SI (1) SI2358686T1 (fr)
SV (1) SV2011003912A (fr)
TN (1) TN2011000209A1 (fr)
UA (1) UA100459C2 (fr)
WO (1) WO2010059773A1 (fr)
ZA (1) ZA201103612B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101651312B1 (ko) * 2009-08-31 2016-08-25 머크 샤프 앤드 돔 코포레이션 피라닐 아릴 메틸 벤조퀴나졸리논 ｍ1 수용체 양성 알로스테릭 조절제
EP2490692B1 (fr) 2009-10-21 2016-11-16 Merck Sharp & Dohme Corp. Composés de quinoléinone-pyrazolone modulateurs allostériques positifs du récepteur m1
US8664387B2 (en) * 2009-12-14 2014-03-04 Merck Sharp & Dohme Corp. Pyridoquinazolinone M1 receptor positive allosteric modulators
PH12012501222A1 (en) 2009-12-17 2012-11-05 Merck Sharp & Dohme Quinoline amide m1 receptor positive allosteric modulators
EP2515656B1 (fr) * 2009-12-21 2014-08-06 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 à base d'aminobenzoquinazolinone
US8557992B2 (en) 2010-06-15 2013-10-15 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
WO2012003147A1 (fr) 2010-07-01 2012-01-05 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 de l'isoindolone
WO2012047702A1 (fr) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 de dihydrobenzoquinazolinone
EP2709624B1 (fr) * 2011-05-17 2016-04-27 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 au n-méthyl tétrahydro-quinoline
JP2014522873A (ja) 2011-08-12 2014-09-08 ビーエーエスエフ ソシエタス・ヨーロピア アントラニルアミド化合物および殺虫剤としてのその使用
AR088786A1 (es) 2011-08-12 2014-07-10 Basf Se Compuestos de antranilamida y sus usos como plaguicidas
WO2013097052A1 (fr) 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
WO2013105117A1 (fr) * 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research Annulation médiée par cu pour la production de dérivés d'acide carboxylique d'1-amino-2-naphtalène
EP2821401B1 (fr) 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Composés de dihydroquinolinone en tant que modulateurs du récepteur muscarinique m1
EP2921480B1 (fr) 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Composé hétérocyclique contenant de l'azote
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
JP6540690B2 (ja) * 2014-04-17 2019-07-10 住友化学株式会社 ニトロ化合物の製造方法
EP3265466A4 (fr) * 2015-03-06 2018-12-26 Chase Pharmaceuticals Corporation Combinaison contenant un anticholinergique périphérique et un agoniste muscarinique
KR20180019234A (ko) 2015-06-26 2018-02-23 다케다 야쿠힌 고교 가부시키가이샤 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
WO2017044693A1 (fr) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
EP3356332A4 (fr) 2015-09-30 2019-06-19 Merck Sharp & Dohme Corp. Procédé de fabrication de modulateurs allostériques positifs du récepteur m1
WO2017058689A1 (fr) * 2015-09-30 2017-04-06 Merck Sharp & Dohme Corp. Formes cristallines d'un modulateur allostérique positif du récepteur m1
JP6787913B2 (ja) * 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
ES2793239T3 (es) 2016-04-15 2020-11-13 Abbvie Inc Inhibidores del bromodominio
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3525588B1 (fr) 2016-10-14 2024-04-24 PI Industries Ltd Phénylamidines 4-substituées et leur application pour la protection de plantes utiles par le combat de microorganismes indésirables
JP7139323B2 (ja) 2016-11-01 2022-09-20 エフ．ホフマン－ラ ロシュ アーゲー Ｃｎｓ関連疾患を処置するための１，３－ジヒドロ－１，４－ベンゾジアゼピン－２－チオン
WO2018212312A1 (fr) 2017-05-19 2018-11-22 武田薬品工業株式会社 Procédé de criblage
BR112021005759A2 (pt) 2018-09-28 2021-07-06 Takeda Pharmaceuticals Co composto, medicamento, métodos de modulação alostérica positiva e para a profilaxia ou o tratamento de constipação, e, uso do composto ou de um sal do mesmo
KR20230158657A (ko) 2021-03-18 2023-11-21 메르크 파텐트 게엠베하 유기 전계 발광 디바이스용 헤테로방향족 화합물
WO2023114224A1 (fr) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda
WO2026051746A1 (fr) * 2024-09-06 2026-03-12 四川科伦药物研究院有限公司 Composé, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856001B1 (fr) * 1995-10-02 2002-08-28 F. Hoffmann-La Roche Ag Derives de pyrimidine en tant qu'antagonistes du recepteur de 5ht2c
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
ATE302199T1 (de) * 1998-10-16 2005-09-15 Sumitomo Pharma Quinalozinon-derivate
JP2005089298A (ja) * 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
EP1596867A4 (fr) * 2003-02-19 2006-03-22 Merck & Co Inc Traitement de la psychose avec un activateur ectopique du récepteur m1 muscarinique
MX2007013606A (es) * 2005-05-04 2007-12-10 Hoffmann La Roche (3,4-dihidro-quinazolin2-il)-(2-ariloxi-etil)-aminas que tienen una actividad en el receptor 5-ht.
US8178667B2 (en) * 2006-06-28 2012-05-15 Merck Sharp & Dohme Corp. Benzyl-substituted quinolone M1 receptor positive allosteric modulators
WO2012047702A1 (fr) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 de dihydrobenzoquinazolinone

Also Published As

Publication number Publication date
EA201170705A1 (ru) 2011-12-30
CN102292323A (zh) 2011-12-21
US9708273B2 (en) 2017-07-18
US20160229813A1 (en) 2016-08-11
HN2011001358A (es) 2014-03-03
DOP2011000135A (es) 2011-07-31
EA019098B1 (ru) 2014-01-30
EP2358686B1 (fr) 2012-09-26
IL212573A0 (en) 2011-06-30
US8557832B2 (en) 2013-10-15
SG171769A1 (en) 2011-07-28
HK1154587A1 (en) 2012-04-27
ZA201103612B (en) 2012-01-25
UA100459C2 (en) 2012-12-25
US8883810B2 (en) 2014-11-11
HRP20120992T1 (hr) 2012-12-31
CA2743562A1 (fr) 2010-05-27
CN102292323B (zh) 2014-12-24
AU2009316578A1 (en) 2011-06-23
MY162502A (en) 2017-06-15
PT2358686E (pt) 2012-12-06
NZ592961A (en) 2012-09-28
KR20110073596A (ko) 2011-06-29
KR101305590B1 (ko) 2013-09-09
JP2012509343A (ja) 2012-04-19
MX2011005284A (es) 2011-06-17
JP5102397B2 (ja) 2012-12-19
RS52528B (sr) 2013-04-30
PL2358686T3 (pl) 2013-02-28
WO2010059773A1 (fr) 2010-05-27
SI2358686T1 (sl) 2013-05-31
PE20120031A1 (es) 2012-02-05
CR20110268A (es) 2011-07-01
GEP20156348B (en) 2015-08-25
SV2011003912A (es) 2011-10-13
EP2358686A1 (fr) 2011-08-24
US20150031713A1 (en) 2015-01-29
DK2358686T3 (da) 2013-01-07
US20110224198A1 (en) 2011-09-15
GT201100127A (es) 2014-02-10
CY1113665T1 (el) 2016-06-22
ECSP11011066A (es) 2011-06-30
NI201100100A (es) 2011-09-12
CO6361928A2 (es) 2012-01-20
US20140005182A1 (en) 2014-01-02
BRPI0921924A2 (pt) 2015-12-29
CA2743562C (fr) 2014-03-18
TN2011000209A1 (en) 2012-12-17
ES2393694T3 (es) 2012-12-27
IL212573A (en) 2015-01-29

Similar Documents

Publication Publication Date Title
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
NZ605431A (en) D2 antagonists, methods of synthesis and methods of use
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
TW200833697A (en) Spiro-piperidine derivatives
DE502007002185D1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
WO2009117283A3 (fr) Modulateurs allostériques positifs du récepteur m1 de la quinolizidine
WO2009134668A3 (fr) Modulateurs allostériques positifs pour le récepteur m1 de 4-oxo-1,4-dihydroquinoléine
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten